Antisense oligonucleotides are recognized to be very efficient tools for the inhibition of gene expression in a sequence specific way. For the discovery of a novel efficient way to modify oligonucleotides, a series of single isonucleotide-incorporated antisense oligodeoxynucleotides have been synthesized, in which an isonucleotide was introduced at different positions of the sequences. The binding behaviors of modified oligodeoxynucleotides to the complementary sequence were studied by UV, CD, and molecular dynamics simulation. The results showed that although the incorporated isonucleotides at certain positions of the sequence interfere with the binding ability to a different extent, B-form duplexes were maintained and the binding abilitie...
Modification of the heterocyclic moiety of oligonucleotides has led to the discovery of potent antis...
Antisense oligonucleotides and siRNAs are potential therapeutic agents and their chemical modificati...
Antisense oligonucleotides are short strands of DNA, which bind to their complementary mRNA target t...
We have designed and synthesized mixed backbone oligonucleotides (MBOs) containing 2'-5'-ribo- and 3...
AbstractTo enhance the penetration of oligonucleotide (‘oligo’) into cells, the oligo was combined w...
Increased evidence shows vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Oligonucleotides have a wide range of applications in fields such as biotechnology, molecular biolog...
The novel oligonucleotide analogue 7, consisting of 1'.4'-anhydro-2',5'-dideoxy-...
Conceptual simplicity, the possibility of rational design, rel-atively inexpensive cost, and develop...
Synthetic oligonucleotides (ONs) constitute an important class of compounds which exhibit biological...
Abstract: Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands o...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Antisense oligonucleotides are short strands of DNA, which bind to their complementary mRNA target t...
Modification of the heterocyclic moiety of oligonucleotides has led to the discovery of potent antis...
Antisense oligonucleotides and siRNAs are potential therapeutic agents and their chemical modificati...
Antisense oligonucleotides are short strands of DNA, which bind to their complementary mRNA target t...
We have designed and synthesized mixed backbone oligonucleotides (MBOs) containing 2'-5'-ribo- and 3...
AbstractTo enhance the penetration of oligonucleotide (‘oligo’) into cells, the oligo was combined w...
Increased evidence shows vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Oligonucleotides have a wide range of applications in fields such as biotechnology, molecular biolog...
The novel oligonucleotide analogue 7, consisting of 1'.4'-anhydro-2',5'-dideoxy-...
Conceptual simplicity, the possibility of rational design, rel-atively inexpensive cost, and develop...
Synthetic oligonucleotides (ONs) constitute an important class of compounds which exhibit biological...
Abstract: Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands o...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Antisense oligonucleotides are short strands of DNA, which bind to their complementary mRNA target t...
Modification of the heterocyclic moiety of oligonucleotides has led to the discovery of potent antis...
Antisense oligonucleotides and siRNAs are potential therapeutic agents and their chemical modificati...
Antisense oligonucleotides are short strands of DNA, which bind to their complementary mRNA target t...